Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Legend Biotech ( (LEGN) ) just unveiled an update.
Legend Biotech has announced a transition agreement with its employee, Lori Macomber, effective January 2, 2025, marking her resignation. During the transition period, Lori will continue her duties and receive her base salary. The agreement outlines severance benefits including salary continuation, a 2024 bonus, COBRA premium payments, and outplacement services. This transition could affect the company’s operational dynamics and stakeholder relationships due to changes in leadership and associated costs.
More about Legend Biotech
Legend Biotech USA Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative cell therapies for oncology and other diseases.
YTD Price Performance: -43.36%
Average Trading Volume: 1,484,132
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.25B
Find detailed analytics on LEGN stock on TipRanks’ Stock Analysis page.
